Research ethics committees have the power to enforce publication of drug trial resultsBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1201 (Published 26 February 2013) Cite this as: BMJ 2013;346:f1201
- Alan S Edwards, retired company director1
- 1Essex Research Ethics Committee, Downham, UK
It seems to me that research ethics committees (RECs) have much more power than medical journals to enforce a higher publication rate by drug companies.1 RECs guard the gateway to patient trials that drug companies badly want, so they have a strong bargaining position.
Yet RECs seem unwilling to step up to their responsibilities, viewing themselves …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial